NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Maralixibat for treating cholestatic pruritus in Alagille syndrome

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
In the initial scope consultation (December 2021), a stakeholder highlighted that the population includes children and that there is a high caregiver burden of caring for a child with cholestasis in Alagille syndrome. They stated that there could be an equalities issue because most caregivers are women. No equality considerations were raised during the (re)scoping workshop (May 2023). The impact on carer quality of life could be assessed during the appraisal if appropriate.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?
Maralixibat is indicated for "cholestatic pruritus in patients with Alagille syndrome 2 months of age and older ". In relation to comments from initial scope consultation, where appropriate and if it applies, the committee will consider whether its recommendations would have a different impact on people with protected characteristics as defined by Equality Act 2010. Consideration may be given to whether further

Technology appraisals: Scoping
Equality impact assessment for the proposed single technology appraisal of maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]
Issue date: September 2023   1 of 2

adjustment should be made to the process and methods during decision making.

3.	Has any change to the draft scope been agreed to highlight potential equality issues?
No changes required.	

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No additional stakeholders related to potential equality issues have been identified.	

Approved by Associate Director (name): ……Janet Robertson………

Date: 04/09/2023

Technology appraisals: Scoping
Equality impact assessment for the proposed single technology appraisal of maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]
Issue date: September 2023   2 of 2